In 2023, China implemented a range of drug regulations, encompassing various aspects such as active pharmaceutical ingredient (API) registration renewal, the outsourcing of manufacturing by marketing authorization holders (MAHs), and drug inspection, among others.
Furthermore, China conducted the bidding process for its 9th national volume-based procurement (VBP) and engaged in price negotiations for the 2023 edition of the National Reimbursement Drug List (NRDL). These initiatives significantly influenced the pricing and market accessibility of pharmaceutical products.
We are hosting this webinar to provide comprehensive coverage of the significant regulatory updates throughout the year. Our goal is to ensure pharma companies are well-informed when devising strategies to enter and expand within the Chinese market.